Besides, several trials are exploring the efficacy of T-DM1 in various non-breast HER2-positive cancers, such as NCT04620187: postoperative or adjuvant treatment of HER2-positive salivary gland carcinomas, NCT03784599: trastuzumab-emtansine/osimertinib combination therapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer with HER2 bypass track resistance, NCT02675829: HER2 amplified or mutant solid tumors, and more. Here, ERBB2 is linked to salivary gland carcinoma.